India approves Pfizer's Viagra
India's Committee of Drugs Control has granted marketing approval toPfizer's male erectile dysfunction drug Viagra (sildenafil), although it may still be some time before the product is available to Indian men. Pfizer is reluctant to launch Viagra in India for fear that it would soon be copied and sold by local manufacturers. The company turned down an offer by the Indian government, extended last year, which would have given the firm a five-year period of exclusivity in the Indian market.
Nevertheless, various Indian firms are said to be gearing up to manufacture sildenafil in India, including Dr Reddy's Labs, Orchid Pharmaceuticals and Ranbaxy Labs (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze